<DOC>
	<DOC>NCT00333138</DOC>
	<brief_summary>This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.</brief_summary>
	<brief_title>Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Core Study Diagnosis of relapsing multiple Sclerosis (MS) Patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year Patients with an Expanded Disability Status Scale (EDSS) score of 06 Extension Study A positive Gdenhanced MRI scan at screening (in case the first MRI scan obtained at screening was negative, a second scan could have been obtained 1 month later) Neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the Screening and Baseline periods. Female patients either postmenopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. Females of childbearing potential with a negative pregnancy test at baseline prior to entry into the treatment period. Core Study Patients with other chronic disease of the immune system, malignancies, pulmonary or heart disease, etc Pregnant or nursing women Extension Study Patients who had permanently discontinued study drug prior to the Month 6 visit of the core study Patients with diabetes mellitus (to reduce the risk of ME), and therefore ongoing patients with diabetes mellitus or who developed diabetes mellitus were discontinued from the study) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>FTY720</keyword>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
</DOC>